Berliner Boersenzeitung - Versameb AG Announces FDA Clearance of IND Application for VMB-100 in the Treatment of Stress Urinary Incontinence

EUR -
AED 3.980447
AFN 76.425222
ALL 100.74696
AMD 436.912951
ANG 1.954503
AOA 898.30222
ARS 392.937771
AUD 1.63805
AWG 1.950986
AZN 1.830865
BAM 1.951392
BBD 2.189653
BDT 119.291604
BGN 1.956511
BHD 0.408517
BIF 3089.061865
BMD 1.083881
BND 1.447842
BOB 7.493072
BRL 5.35958
BSD 1.08445
BTN 90.420727
BWP 14.694735
BYN 3.572763
BYR 21244.074583
BZD 2.185952
CAD 1.467548
CDF 2893.963137
CHF 0.945568
CLF 0.034096
CLP 940.808739
CNY 7.734791
COP 4357.744993
CRC 573.90347
CUC 1.083881
CUP 28.722856
CVE 110.826602
CZK 24.417627
DJF 192.627202
DKK 7.455584
DOP 61.557616
DZD 146.104707
EGP 33.515666
ERN 16.25822
ETB 60.374282
FJD 2.417869
FKP 0.85335
GBP 0.85786
GEL 2.92428
GGP 0.85335
GHS 13.017525
GIP 0.85335
GMD 73.026481
GNF 9326.799239
GTQ 8.494887
GYD 227.067023
HKD 8.471671
HNL 26.770562
HRK 7.632226
HTG 143.435958
HUF 380.062499
IDR 16783.360861
ILS 4.036401
IMP 0.85335
INR 90.413427
IQD 1419.884577
IRR 45807.532299
ISK 150.897687
JEP 0.85335
JMD 168.251448
JOD 0.768909
JPY 159.598269
KES 166.104771
KGS 96.78645
KHR 4462.339992
KMF 490.401878
KPW 975.493515
KRW 1421.153046
KWD 0.334865
KYD 0.903754
KZT 501.148586
LAK 22436.343756
LBP 16370.728438
LKR 355.899971
LRD 203.932469
LSL 20.170719
LTL 3.20042
LVL 0.655629
LYD 5.221253
MAD 10.92606
MDL 19.232551
MGA 4877.466372
MKD 61.637824
MMK 2277.344646
MNT 3720.175292
MOP 8.730676
MRO 386.945458
MUR 47.940177
MVR 16.648524
MWK 1825.799041
MXN 18.932167
MYR 5.051374
MZN 68.555442
NAD 20.171174
NGN 866.021711
NIO 39.848861
NOK 11.747209
NPR 144.673163
NZD 1.758159
OMR 0.417281
PAB 1.084445
PEN 4.050886
PGK 4.047103
PHP 59.990126
PKR 308.635039
PLN 4.329727
PYG 8045.897394
QAR 3.946141
RON 4.968535
RSD 117.329505
RUB 99.166197
RWF 1349.34541
SAR 4.065874
SBD 9.18692
SCR 14.326736
SDG 651.412944
SEK 11.299842
SGD 1.449853
SHP 1.318813
SLE 24.642059
SLL 21406.656447
SOS 619.442693
SRD 40.752891
STD 22434.155727
SYP 14092.607289
SZL 20.171012
THB 38.192721
TJS 11.84758
TMT 3.793585
TND 3.374176
TOP 2.555904
TRY 31.346388
TTD 7.35239
TWD 34.042565
TZS 2715.121734
UAH 39.655031
UGX 4115.702038
USD 1.083881
UYU 42.444503
UZS 13337.16012
VEF 3851696.775976
VES 38.51697
VND 26289.542296
VUV 128.697593
WST 2.90817
XAF 654.475427
XAG 0.044198
XAU 0.000533
XCD 2.929244
XDR 0.813969
XOF 651.412677
XPF 119.064483
YER 271.349422
ZAR 20.378705
ZMK 9756.23296
ZMW 25.836631
ZWL 349.009354
  • NGG

    -0.6300

    66.21

    -0.95%

  • BCC

    2.1800

    114.57

    +1.9%

  • CMSC

    -0.1300

    24.48

    -0.53%

  • SCS

    -0.0200

    12.44

    -0.16%

  • CMSD

    -0.2800

    24.05

    -1.16%

  • SLAC

    -0.0700

    10.27

    -0.68%

  • BTI

    -0.1100

    31.93

    -0.34%

  • RIO

    -2.1100

    69.05

    -3.06%

  • AZN

    0.2300

    65.02

    +0.35%

  • SCU

    -0.0300

    12.72

    -0.24%

  • GSK

    0.0600

    36.63

    +0.16%

  • RYCEF

    0.1060

    3.636

    +2.92%

  • BCE

    0.2900

    40.6

    +0.71%

  • JRI

    0.0400

    11.32

    +0.35%

  • RBGPF

    0.0260

    68.036

    +0.04%

  • RELX

    0.0300

    38.59

    +0.08%

  • BP

    -0.3900

    35.59

    -1.1%

  • VOD

    -0.1800

    9.04

    -1.99%

Versameb AG Announces FDA Clearance of IND Application for VMB-100 in the Treatment of Stress Urinary Incontinence
Versameb AG Announces FDA Clearance of IND Application for VMB-100 in the Treatment of Stress Urinary Incontinence

Versameb AG Announces FDA Clearance of IND Application for VMB-100 in the Treatment of Stress Urinary Incontinence

BASEL, Switzerland, Nov. 16, 2023 /PRNewswire/ -- Versameb AG ("Versameb"), a pre-clinical stage company focused on transforming RNA therapeutics to treat unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application of VMB-100, a potency enhanced messenger ribonucleic acid (mRNA) encoding human insulin-like growth factor-1 (IGF-1), for the treatment of stress urinary incontinence (SUI).

Text size:

Following this clearance, Versameb plans to launch a Phase 2a open label, first-in-human dose ascending study in the first half of 2024. The study will evaluate the safety, tolerability, and efficacy of VMB-100 in female subjects with stress urinary incontinence, a highly common condition resulting in involuntary leakage of urine due to a weakened urinary sphincter muscle.

"The IND clearance by the FDA represents a significant milestone for the VMB-100 development program and for Versameb," said Klaas Zuideveld, Chief Executive Officer of Versameb AG. "This brings us a step closer to providing an effective therapeutic option to patients suffering from SUI. Our proprietary VERSagile platform is uniquely designed to improve potency of mRNA therapeutics and we believe VMB-100 can potentially become a game changer for SUI treatment. We look forward to initiating this trial in the first half of 2024 to evaluate the potential clinical benefits of VMB-100 in SUI."

"Stress urinary incontinence significantly impacts the quality of life of millions of women globally and is a major unmet medical need with no approved therapeutics available currently," said Professor Roger Dmochowski, Chief Medical Officer of Versameb AG. "IGF-1 plays a key role in promoting muscle regeneration and re-establishment of muscle function. We believe VMB-100 has the potential to fill the current therapeutic gap as a first-in-class mRNA therapy that can restore muscle function and thereby effectively treat incontinence."

About VMB-100

VMB-100 is an intramuscularly locally delivered, sequence engineered messenger ribonucleic acid (mRNA) encoding for human insulin-like growth factor-1 (IGF-1) under investigation for the treatment of stress urinary incontinence (SUI). VMB-100 has the potential to become first-and best-in-class in sustained muscle regeneration following short-term treatment. In preclinical studies, it has been demonstrated that VMB-100 induced the expression of IGF-1 levels in human muscle cells. In animals models of SUI, VMB-100 accelerated regeneration of the urinary sphincter muscle and restored urinary sphincter function after a single dose of treatment. Versameb plans to launch a Phase 2a open label, first-in-human dose ascending study of VMB-100 in female subjects with moderate stress urinary incontinence in the first half of 2024.

About Stress Urinary Incontinence

Stress urinary incontinence is a common condition amongst women in which a leakage of urine occurs during moments of physical activity due to a weakened urinary sphincter muscle. SUI is the most common type of urinary incontinence, affecting 86% of incontinent women. Despite the prevalence of SUI, there are currently no approved pharmacological therapies available in the United States. Current standard of care protocol includes short-term solutions like pelvic floor therapy or a highly invasive surgical procedure in which a sling is permanently implanted into the urethra or bladder neck.

About Versameb AG

Versameb AG is a privately held biotechnology company focusing on discovering and developing innovative RNA-based drugs for modulation of protein expression, including the ability to simultaneously influence several therapeutic targets, in a controlled manner, with one molecular construct, and cellular targeting. Based in Basel and fully operational since 2018, the company is led by an experienced scientific and leadership team with proven expertise in drug discovery and development from lab bench to patient. Versameb's proprietary technology platform, VERSagile, optimizes the application of functional RNA in different disease contexts. The pipeline includes lead candidate programs in stress urinary incontinence (SUI), solid tumors and rare diseases. Versameb is working towards the completion of a first in-human proof-of-concept clinical study while advancing its platform. More information on Versameb can be found at www.versameb.com as well as on LinkedIn.

(S.G.Stein--BBZ)